RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Metabolon, Inc., the leader in metabolomics, biomarker discovery and analysis, announced today the grant of US Patent No. 7,884,318 entitled “Systems, ...
Please acknowledge the SIP core facility ( RRID: SCR_018986) in publications, on posters, or in talks if you use any instruments in the SIP core facility. Please include SIP's RRID (RRID: SCR_018986) ...
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations ...
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy In prostate cancer, end points that reliably portend prognosis and treatment benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback